Skip to main content

Table 3 The marginal annual cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Jacobs et al.’s [24] model

From: Exploring the role of an unsanctioned, supervised peer driven injection facility in reducing HIV and hepatitis C infections in people that require assistance during injection

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Benefit-cost ratio HCV

Benefit-cost ratio HIV

Cost-benefit ratio total

One SIF

$97,203

25 %

30

81

$1,200

$3,240

29.3

64.9

94.3

  

(33 %, 16 %)

(40, 20)

(103, 59)

($944, $1,648)

($2,430, $4,860)

(37.2, 21.3)

(86.6, 43.3)

(102.2, 64.7)

Two SIFs

$97,203

19 %

29

79

$1,230

$3,352

28.6

62.8

91..4

  

(26 %, 13 %)

(39, 38)

(103, 104)

($944, $1,869)

($2,492, $5,116)

(37.2, 18.8)

(84.5, 41.2)

(121.7, 60.0)

Three SIFs

$97,203

18 %

7

19

$5,115

$13,886

6.9

15.2

22.0

  

(24 %, 12 %)

(9, 44)

(29, 118)

($3,352, $2,471)

($10,800, $6,628)

(10.5, 14.2)

(19.5, 31.8)

(25.7, 46.0)

Four SIFs

$97,203

16 %

8

23

$4,226

$12,150

8.3

17.3

25.6

  

(22 %, 11 %)

(12, 50)

(29, 133)

($3,352, $2,923)

($8,100, $7,776)

(10.5, 12)

(26, 27.1)

(25.6, 39.1)

Five SIFs

$97,203

15 %

9

24

$4,050

$10,800

8.7

19.5

28.2

  

(19 %, 10 %)

(14, 56)

(44, 148)

($2,209, $3,284)

($6,943, $8,679)

(15.9, 10.7)

(30.3, 24.3)

(28.2, 35.0)

Six SIFs

$97,203

13 %

9

25

$3,888

$10,800

9

19.5

28.5

  

(18 %, 9 %)

(10, 62)

(14, 163)

($6,943, $3,578)

($9,720, $9,407)

(5.1, 9.8)

(21.6, 22.4)

(26.7, 32.2)

Seven SIFs

$97,203

12 %

8

22

$4,418

$12,150

7.9

17.3

25.3

  

(15 %, 8 %)

(12, 68)

(44, 177)

($2,209, $3,844)

($8,100, $1,006)

(15.9, 3.51)

(26, 21)

(33.2, 30.2)

  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (40 per cent sharing rate, 20 percent sharing rate)